Reported about 12 hours ago
San Diego startup Gallant has announced $18 million in funding to develop the first FDA-approved ready-to-use stem cell therapy for veterinary applications, targeting conditions like Feline Chronic Gingivostomatitis in cats. This innovative therapy uses donor animal cells, making it more convenient than traditional methods that require harvesting from patients. Early studies show promising results for treating arthritis in dogs, with potential FDA approval for Gallant's treatment expected by early 2026.
Source: YAHOO